Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093965 | 0.88 | MAPT (0.57) | MAPTTSHREPHX2KDM4ECNR1 | |
| SCHEMBL14602602 | 0.84 | CNR1 (0.62) | MAPTTSHREPHX2KDM4ECNR1 | |
| SCHEMBL10126547 | 0.84 | TSHR (0.59) | MAPTTSHRKDM4ECNR1PARP1 | |
| SCHEMBL17774880 | 0.83 | HSP90AA1 (0.57) | MAPTTSHRKDM4EHTTSMN1; SMN2 | |
| SCHEMBL17400734 | 0.83 | MAPT (0.52) | MAPTTSHREPHX2KDM4ECNR1 | |
| SCHEMBL16379735 | 0.82 | MAPT (0.57) | MAPTTSHREPHX2KDM4ECNR1 | |
| SCHEMBL1438540 | 0.82 | MAPT (0.57) | MAPTTSHREPHX2KDM4ECNR1 | |
| SCHEMBL15597416 | 0.82 | KDM4E (0.73) | MAPTTSHRKDM4ECNR1HTT | |
| SCHEMBL17979877 | 0.82 | MEN1 (0.55) | MAPTTSHRKDM4ECNR1HTT | |
| SCHEMBL256984 | 0.82 | TSHR (0.57) | MAPTTSHREPHX2KDM4ECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385406-A1 | SUBSTITUTED HETEROCYCLIC-PYRIDINONES AS HIV-1 NEF-HCK INHIBITORS | SOUTHERN RESEARCH INSTITUTE | 2020-12-10 | — | — | US | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385406-A1 | SUBSTITUTED HETEROCYCLIC-PYRIDINONES AS HIV-1 NEF-HCK INHIBITORS | HCK, PDXK, NADK | MAPT 1498/4885TSHR 4511/4885EPHX2 3210/4885 |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | MAPT 3654/4885TSHR 3492/4885EPHX2 2295/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | MAPT 2007/4885TSHR 1504/4885EPHX2 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.